In addition, the NRF2 molecular signature, including genes important in activating TRX and GSH systems such as glutathione peroxidase (GPX) 3 and thioredoxin-like 1, is suggested as an excellent predictor of cancer remission and overall survival in patients with lung cancer [57]. This evidence concerns the gene NFE2L2 and lung carcinoma.